Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis

Indian Journal of Medical Research

Volumn 136, Issue 5, 2012, Pages 808-814

  Ahmad, Zahoor ^a   Tyagi, Sandeep ^a   Minkowski, Austin ^a   Almeida, Deepak ^a   Nuermberger, Eric L ^a   Peck, Kaitlin M ^b   Welch, John T ^b   Baughn, Anthony S ^c   Jacobs, Williams R ^c   Grosset, Jacques H ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Experimental chemotherapy; Mouse; Pyrazinamide; Tuberculosis

Indexed keywords

5 CHLORO PYRAZINAMIDE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN;

EID: 84872087742     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Gu P, Constantino L, Zhang Y. Enhancement of the antituberculosis activity of weak acids by inhibitors of energy metabolism but not by anaerobiosis suggests that weak acids act differently from the front-line tuberculosis drug pyrazinamide. J Med Microbiol 2008; 57: 1129-34.
2. Wade MM, Zhang Y. Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis. J Med Microbiol 2004; 53: 769-73.
3. Steele MA, Des Prez RM. The role of pyrazinamide in tuberculosis chemotherapy. Chest 1988; 94: 845-50.
4. Konno K, Nagayama H, Oka S. Nicotinamidase in mycobacteria: a method for distinguishing bovine type tubercle bacilli from other mycobacteria. Nature 1959; 184: 1743-4.
5. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003; 7: 6-21.
6. Zhang Y, Wade MM, Scorpio A, Zhang H, Sun Z. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother 2003; 52: 790-5.
7. Zimhony O, Cox JS, Welch JT, Vilchèze C, Jacobs WR, Jr. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med 2000; 6: 1043-7.
8. Konno K, Feldmann FM, McDermott W. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am Rev Respir Dis 1967; 95: 461-9.
9. Scorpio A. Lindholm-Levy P, Heifets L, Gilman R, Siddiqi S, Cynamon M, et al. Characterization of the pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997; 41: 540-3.
10. Scorpio A, Zhang Y. Mutations in pncA a gene encoding pyrazinamidase/nicotin-amidase cause resistance to the antituberculosis drug pyrazinamide in M. tuberculosis. Nature Med 1996; 2: 662-7.
11. Gangadharam PRJ, Iseman MD. Antimycobacterial drugs. In: Peterson PK, Verhoef J, editors. The antimicrobial agents annual. New York: Elsevier; 1986. p. 17-40.
12. Cynamon MH, Gimi R, Gyenes F, Sharpe CA, Bergmann KR, Han HJ, et al. Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity. J Med Chem 1995; 38: 3902-7.
13. Cynamon MH, Klemens SP, Chou TS. Antimycobacterial activity of a series of pyrazinoic acid esters. J Med Chem 1992; 35: 1212-5.
14. Cynamon MH, Speirs RJ, Welch JT. In Vitro antimycobacterial activity of 5-chloropyrazinamide. Antimicrob Agents Chemother 1998; 42: 462-3.
15. Tyagi S, Nuermberger E, Yoshimatsu T, Williams K, Rosenthal I, Lounis N, et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 2005; 49: 2289-3.
16. Williams KN, Stover CK, Zhu T, Zhu T, Ogden A, Tasneen R, et al. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 2009; 53: 1314-9.
17. Ahmad Z, Nuermberger EL, Tasneen R, Pinn ML, Williams KN, Peloquin CA, et al. Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. J Antimicrob Chemother 2010; 65: 729-34.
18. Almeida D, Nuermberger EL, Tasneen R, Rosenthal I, Tyagi S, Williams K, et al. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrob Agents Chemother 2009; 53: 4178-84.
19. Grosset J. The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Bull Int Union Tuberc 1978; 53: 5-12.
20. Grosset J, Truffot-Pernot C, Lacroix C, Ji B. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 1992; 36: 548-51.